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1755-1 1 Early Angioplasty During Hospitalization for Acute
Myocardial Infarction Improves 3-Year Survival
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There was a trend to a decrease in LA-EV and LA-FV post-conversion to
NSR (p < 0.05 for group 1 and all pts combined). The left ventricular ejec-
tion fractions pre-ECV were not significantly different between groups (55 ±
11 % vs 46 ± 9%, P = NS). Spontaneous contrast was present in 6 pts in
group 1 (86%) and 4 pts in group 2 (44%) at baseline and worsened in 1 pt in
group 1 (14%) and 3 pts in group 2 (33%) only after conversion to NSR. One
pt in group 1 and 3 pts in group 2 had no spontaneous contrast at baseline
and developed it only after conversion to NSR. In conclusion: 1) Decreased
left atrial mechanical function occurs after conversion to NSR. 2) Left atrial
mechanical function is not significantly decreased after ineffective ECV at-
tempts. 3) Spontaneous contrast was found more often in pts requiring less
energy for cardioversion. 4) Spontaneous contrast worsened more often in
pts requiring more energy for conversion to NSR and worsened only after
conversion to NSR. 5) These findings suggest that left atrial "stunning" and
worsening stasis of flow is due to conversion to NSR and not secondary to
ineffective ECV attempts.
We studied the effect on survival of PTCA during hospitalization for acute
myocardial infarction (MI) in 42,595 patients from the MIDAS registry in New
Jersey (years 1986-87). The 3-year unadjusted death rate was high, 36.0%
in the absence of PTCA, but much lower, only 8.7%, in the 684 patients un-
dergoing PTCA [7.7% (40/508) in men, and 11.7% (21/176) in women]. Early
revascularization (PTCA in first 24 hours after admission) was performed in
41 % of the patients. Multivariate Cox proportional hazards regression anal-
ysis was performed, including previously reported predictors of death fol-
lowing PTCA such as female sex, advanced age, impaired left ventricular
function and prior MI, along with variables describing co-morbidity, race and
insurance coverage. The adjusted death rate ratios (RR, 95% C.I.) associated
with performance of early or late PTCA are noted below.
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developed nonsustained PVT during or shortly after the infusion (11 of 15
occurred during the first infusion).
Conclusions: Ibutilide given in repeated doses is highly effective compared
to placebo in rapidly terminating chronic atrial fibrillation or flutter and un-
der monitored conditions is a potential alternative to currently available car-
dioversion options.
Continuous Transesophageal Echocardiography
During Sequential Electrical Cardioversion Attempts
for Atrial Fibrillation: Effect on Left Atrial Appendage
Function and Spontaneous Contrast Formation
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1754-51 A Multi-Centre Double Blind Crossover Comparison
of Disopyramide, Atenolol, and Placebo for
Symptomatic Paroxysmal Atrial Fibrillation
Francis D. Murgatroyd, Dympna M. O'Farrell, John P. Foran, Stephen J. Kelly, David
E. Ward, A. John Camm, Controlled Randomized Atrial Fibrillation Trial
Investigators. St George's Hospital Medical School, London UK
Class la drugs and II-blockers are commonly used to treat symptomatic
paroxysmal atrial fibrillation (PAF), and patients with "vagal" and "adrener-
gic" patterns of PAF onset are held to respond to anticholinergic and fJ-
blocking agents, respectively. However, neither class has been subjected to
controlled clinical trials in this condition. CRAFT-2 was a double blind three-
way crossover comparison of atenolol (At) (initial dose 100 mg daily). disopy-
ramide (Dp) (initial dose 450 mg daily), and matched placebo (PI). The primary
endpoint was the time to the first and second attacks of PAF, documented by
transtelephonic monitoring, with a maximum of two attacks or two months
on each treatment. All patients completed a 1O-item symptom questionnaire
aimed at identifying vagal and adrenergic patterns of arrhythmia onset.
75 patients from 7 hospitals were screened for CRAFT-2, and 30 were
randomized; their clinical characteristics closely approximated those of 334
patients with PAF in the CRAFT registry. The numbers of patients with 0 and
<2 attacks on placebo were 0, and 1, respectively. On At, these were 6 and
7, and on Dp 5 and 6, respectively. The median times to the first and second
attack were 4.2 and 7.5 days on PI, 4.4 (p = 0.08) and 16.4 (p = 0.031 days on
Dp, and 12.4 (p ~ 0.007) and 29.1 (p = 0.008) days on At, respectively. The
mean (SO) heart rates during attacks were 130 (21) beatslmin on PI, 135 (26)
on Dp. (p = NS), and 115 (23) on At Ip = 0.02). Dose reductions due to side-
effects were required in 0, 2, and 4 cases, and treatment withdrawal was
required in 0, 1, and 1 cases during PI. Dp, and At treatment, respectively.
There was no clear relationship between autonomic patterns of symptom
onset and the response to treatment.
We conclude that disopyramide and especially atenolol reduce the fre-
quency of symptomatic episodes of PAF. The efficacy of atenolol may relate
to symptom reduction because of a lower heart rate, but that of disopyra-
mide is likely to be a true antiarrhythmic action. The pattern of symptom
onset does not easily predict response to individual antiarrhythmic agents.
Rita A. Falcone, Fred Morady, William F. Armstrong. University of Michigan, Ann
Arbor. MI
Electrical cardioversion (ECV) of atrial fibrillation to normal sinus rhythm
(NSR) is associated with an increased risk of stroke presumably from left
atrial mechanical "stunning" and subsequent stasis of blood. The effect of
ineffective electrical shocks on the mechanical function of the left atrium and
the formation or worsening of spontaneous contrast is unknown. We stud-
ied 16 pts with atrial fibrillation (>2 days) pre and post each ECV attempt
during continuous transesophageal echocardiography. ECV was performed
at 50, 100,200, then 360J until NSR was achieved. Group 1 (N = 7) required
50J and group 2 (N = 9) >50J for conversion to NSR. Left atrial appendage
emptying (LA-EV) and filling velocities (LA-FV) were measured (m/sec) with
pulsed wave Doppler and spontaneous contrast was graded visually pre- and
post- each ECV attempt.
LA-EV
pre 50J 100J NSR
all pts 0.41 ± 0.12 0.28 ± 0.16'
grp 1 0.42 ± 0.11 0.25 ± 015" 0.25 ± 0.15'
grp 2 0.40± 0.14 0.36 ± 0.15 0.60 ± 0.23 0.28 ± 0.17
LA-FV
pre 50J 100J NSR
all pts 0.47±0.18 0.33 ± 0.14'
grp 1 0.44 ± 0.08 0.30 ± 0.15'
--* 0.30 ± 0.15'
grp 2 0.47 ± 0.23 0.42±0.15 0.39 ± 0.16 0.33 ± 0.15
, pre vs NSR. p < 0.05
ConClusion: Early PTCA during hospitalization for acute MI is indepen-
dently associated with a 50% reduction in 3-year death risk in the middle-age
and oldest groups after controlling for all the other factors in the Cox model.
The benefit is also observed with late PTCA, but only achieves statistical sig-
nificance in the oldest group.
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1755-21 Current Management of ST Elevation Myocardial
Infarction and Outcome of Thrombolytic Ineligible
Patients: Results of the Multicenter TIMI 9 Registry
Christopher P. Cannon, Timothy D. Henry, Marc J. Schweiger, J. Mark Haugland,
George R. McKendall, Prediman K. Shah, Ray Gleason, Carolyn H. McCabe, Elliott
M. Antman, Eugene Braunwald, TIMI 9 Registry Investigators and Coordinators.
Brigham and Women's Hospital, Boston, MA
Despite clear benefit of thrombolysis (Tlysis) and primary (1 ') PTCA for acute
MI, prior reports have indicated a low use of thrombolytic therapy in the U.S.
Further, single center reports have suggested that mortality is up to 5 times
higher when thrombolysis is not given. To evaluate the management and
outcome of acute MI in 1994, we conducted a registry in 20 hospitals (16
with l' PTCA capability) and prospectively identified all consecutive patients
(ptsl presenting with acute MI and ST segment elevation or new LBBB. A
total of 587 pts were identified, 200 were enrolled in the TIM I 9 thrombolytic
trial of hirudin vs. heparin, and 387 in the TIMI 9 Registry. Tlysis was given
to 356 of 587 (60.7%) pts (of whom 200/356 (56%) were enrolled in TIMI
9); l' PTCA was performed in 62/587 (10.5%) of the total population and
medical therapy used in 169/587128.8%). Of the patients enrolled in the TIMI
9 Registry, those treated with l' PTCA were significantly younger, 60.7 years,
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vs. 64.9 for Tlysis and 66.1 for medical therapy(each p < 0.05) and were less
often women, 20.0%, vs. 36.2% and 36.1 %, respectively, (each p < 0.05).
Time to presentation was significantly longer for medically treated pts: 13.8h
vs. 4.4h for Tlysis and 3.3h for 10 PTCA (each p < 0.001). Delay> 12 hours
was the reason cited most often for pts not treated with thrombolysis. In-
hospital mortality is shown. Recurrent MI was similar in the 3 groups, 4.2%.
Conclusions: 11) In 1994 in the U.S., reperfusion therapy was used in 71 % of
pts with ST elevation MI at these hospitals. (2) The potential underutilization
of l' PTCA in women deserves further study. (3) Early mortality was similar
for Tlysis and l' PTCA, but highest for medically treated pts, which supports
further expansion of reperfusion therapy in ST elevation MI (including use of
strategies to shorten patient time to presentation) and the need for improved
medical therapies for thrombolytic ineligible patients.
TlMI9 Registry
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Does a Less Restrictive Indication for Thrombolytic
Therapy Cause More Iatrogenic Complications in
Acute Myocardial Infarction?
Udo Burczyk, Jbrg Rustige. Rudolf Schiele, Armin Koch, Rainer Uebis.
Jochen Senges, ALKK-Study-Group. Herzzentrum Ludwigshafen, Department of
Cardiology, Germany
Purpose: In consideration of possible severe complications thrombolytic
agents are administered to only 30% of patients with acute myocardial in-
farction (AMI) admitted to coronary care units in Western Europe. "The 60-
Minutes Myocardial Infarction Project" therefore investigates the effect of a
higher lysis rate (LR) on the frequency of complications.
Methods: The multicenter nationwide study includes 154 hospitals in Ger-
many. During an 8-month period 4650 consecutive patients with proven
transmural AMI were enrolled and complications occurring within 48 hours
after admission were registered for clinical centers with a low and high LR
1~50% versus >50%).
Results:
clinical centers: all LR < 50% LR > 50%
complications (within 48 h): n ~ 4650 n = 2768 n ~ 1882
death 8.0% 8.3% 7.5%
hemorrhagic stroke 0.4% 0.5% 0.2%
ventricular rupture 0.4% 0.4% 0.4%
moderate bleeding 2.4% 1.8% 3,3%
allergic reaction 0.8% 0.5% 1.3%
Christopher Granger. Harvey White. Maarten Simoons, Douglas Weaver, Joel Gore,
Phil Aylward. Gabriel Barbash. Kerry Lee. Robert Califf. GUSTO Investigators.
Duke University Medical Center; Durham, NC
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1755-51 Risk Factors for Stroke Following Thrombolytic
Therapy: Case-Control Study from the GUSTO Trial
In order to determine risk factors for stroke beyond the standard known fac-
tors of age. presenting blood pressure, weight. sex, and history of hyper-
tension which were collected on all patients in the GUSTO Trial. additional
data were collected for the 592 patients suffering stroke as well as 548 age-
matched controls. Odds ratios 195% el) were as follows:
For hemorrhagic stroke
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Facial or head trauma within 2 wks
History of stroke
Dementia
Atrial fibrillation
Warfarin use
Nonsteroidal anti-inflam matory use
Calcium blocker use
Beta blocker use
Both groups were similar in age, sex and coexisting diseases.
Conclusions: 1. 48-hour mortality was lower in clinical centers with a higher
LR. 2. Severe complications showed no significant difference. 3. Minor com-
plications were significantly more frequent in clinical centers with a higher
LR. 4. These results support a less restrictive indication for thrombolytic ther-
apy in AMI based on individual benefit-risk evaluation.
David J. Moliterno. Christopher Granger, Robert M. Califf. John M. Elliott.
Amanda Stebbins, Eric J. Topol, GUSTO Investigators. The Cleveland Clinic
Foundation. Cleveland, OH
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Previous studies of thrombolysis in acute myocardial infarction (AMI) have
noted lower efficacy in heavy patients and a higher incidence of bleeding
complications among lighter patients. In the GUSTO trial of 41 ,021 patients
receiving either streptokinase, a weight-adjusted dose of t-PA. or combina-
tion therapy for AMI, we prospectively collected data on patient weight and
postulated prognostic value based on this variable. Patients with increased
body mass were hypothesized to have reduced thrombolytic efficacy. Sur-
vival, along with moderate and severe bleeding complications, were there-
fore analyzed according to weight subgroups separated into deciles. Para-
doxically, inverse relationships between patient body weight and both bleed-
ing and mortality were demonstrated regardless of thrombolytic treatment
strategy. Moreover, in a multivariable model of predictors of mortality, pa-
tient body weight added significant independent prognostic information (X 2
= 19, P < 0.0001). In conclusion, an inverse relationship to mortality was
present throughout the weight range of patients. In contrast to previous ob-
servations, heavy weight patients actually have an improved prognosis.
1755-31 Improved Prognosis for Heavy Weight Patients
Receiving Thrombolysis in Acute Myocardial
Infarction - Bigger is Better: Results from GUSTO
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These findings suggest that recent facial or head trauma is a strong risk
factor for hemorrhagic stroke following thrombolytic therapy, and therefore
should generally be considered to be a contraindication to thrombolytic
therapy. History of stroke predisposes to both any stroke and hemorrhagic
stroke, and dementia appears to predispose to hemorrhagic stroke.
1755-61 Neurosurgical Evacuation for Intracranial
Hemorrhage Associated with Improved Outcome in
GUSTO
Kenneth W. Mahaffey. Harvey D. White. Christopher B. Granger, Robert M. Califf,
Joel M. Gore. W. Douglas Weaver. Maarten L. Simoons. Gabriel!. Barbash,
Michael A. Sloan, Eric J. Topol, GUSTO Investigators. Duke University Medical
Center. Durham, NC
In order to evaluate the impact of neurosurgical evacuation of intracranial
hemorrhage IICH) following thrombolytic therapy for acute myocardial infarc-
tion, we analyzed the 268 patients with ICH in the GUSTO Trial. In-hospital
mortality was 60% with only 13% of patients discharged with minor or no
disability. Of the 268 patients, 47 had neurosurgical intervention with the fol-
lowing results:
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